Sveriges Riksbank
5.3.2021 16:21:54 CET | Globenewswire | Press release
| Bid procedure, 2021-03-08 | |
| Bills | SWEDISH T-BILL: SE0015504907. 2021-05-19 SWEDISH T-BILL: SE0014808747, 2021-09-15 |
| Bid date | 2021-03-08 |
| Bid times | 09.00-10.00 (CET/CEST) on the Bid date |
| Requested volume (corresponding nominal amount) | SE0015504907: 500 mln SEK +/-250 mln SEK SE0014808747: 500 mln SEK +/-250 mln SEK |
| Highest permitted bid volume (corresponding nominal amount) | SE0015504907: 500 mln SEK per bid SE0014808747: 500 mln SEK per bid |
| Lowest permitted bid volume (corresponding nominal amount) | SEK 50 million per bid |
| Expected allocation time | Not later than 10.15 (CET/CEST) on the Bid date |
| Delivery and payment date | 2021-03-10 |
| Delivery of bills | To the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 |
Stockholm, 2021-03-05
This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
KAYTUS SYSTEMS PTE. LTD.29.9.2026 03:30:22 CEST | Press release
KAYTUS KR2166V3 Accelerates AIHPC Data Processing at Petabyte Scale
Evosep29.9.2026 03:00:00 CEST | Press release
Evosep and Mass Dynamics Join Forces to Standardize Proteomics Sample Preparation for Pharma
Oatly Group AB (publ)28.9.2026 22:05:00 CEST | Press release
Oatly to Report Third Quarter 2026 Financial Results on October 28, 2026
Teva Pharmaceutical Industries Ltd28.9.2026 22:00:00 CEST | Press release
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
Unlimit Group A/S28.9.2026 20:22:13 CEST | Pressemeddelelse
Unlimit Group A/S: Sikrer ny kapital og styrker balancen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
